Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis.
……………
Sutherland JE, Hettinger JL, Chan A, Gilbert J, Warner GL, Davis WP.
Nucleic Acid Ther. 2019 Dec 10.